Lorraine Flet-Berliac
Overview
Explore the profile of Lorraine Flet-Berliac including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazowiecki M, Flet-Berliac L, Roux J, Lepine A, Chretien P, Hacein-Bey-Abina S, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Dec;
12(2):e200346.
PMID: 39715492
Background And Objectives: Anti-NMDAR encephalitis (NMDARE) is a severe neurologic condition, and recently, the NMDAR Encephalitis One-Year Functional Status (NEOS) score has emerged as a 1-year prognostic tool. This study...
2.
Horellou P, Flet-Berliac L, Leroy C, Giorgi L, Joly C, Desjardins D, et al.
Brain Commun
. 2023 Mar;
5(2):fcad063.
PMID: 36993944
Acquired demyelinating syndrome associated with myelin oligodendrocyte glycoprotein antibodies, named recently myelin oligodendrocyte glycoprotein-associated disease, represents >27% of this paediatric syndrome. Relapses occur in 40% of them, which may be...
3.
Flet-Berliac L, Tchitchek N, Lepine A, Florea A, Maurey H, Chretien P, et al.
Dev Med Child Neurol
. 2022 Oct;
65(5):691-700.
PMID: 36196688
Aim: To study long-term clinical and cognitive outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis (NMDAR-E), an acute autoimmune neurological disease with severe acute presentations. Method: In this French multicentre retrospective...
4.
Bruijstens A, Wendel E, Lechner C, Bartels F, Finke C, Breu M, et al.
Eur J Paediatr Neurol
. 2020 Nov;
29:41-53.
PMID: 33176999
In recent years, the understanding about the different clinical phenotypes, diagnostic and prognostic factors of myelin oligodendrocyte glycoprotein-antibody-associated disorders (MOGAD) has significantly increased. However, there is still lack of evidence-based...
5.
Bruijstens A, Lechner C, Flet-Berliac L, Deiva K, Neuteboom R, Hemingway C, et al.
Eur J Paediatr Neurol
. 2020 Nov;
29:2-13.
PMID: 33162302
Over the past few years, increasing interest in the role of autoantibodies against myelin oligodendrocyte glycoprotein (MOG-abs) as a new candidate biomarker in demyelinating central nervous system diseases has arisen....